In Vitro Pharmacology of Mitragynine at α-Adrenoceptors
Mitragynine is a psychoactive alkaloid in <i>Mitragyna speciosa</i> with unique polypharmacology at G protein-coupled receptors. In addition to its well-known partial agonist activity at opioid receptors, mitragynine is an antagonist at human α<sub>2A</sub>-adrenoceptors (α<sub>2A</sub>Rs), as measured in an in vitro GTPγS G protein assay. Mitragynine's in vitro α<sub>2A</sub>R antagonist pharmacology contrasts with rat behavioral pharmacology studies that suggest mitragynine behaves as an in vivo agonist at rat α<sub>2</sub>Rs. This study investigates this apparent discrepancy using recombinant α-adrenoceptors and a range of orthogonal signal transducers. We evaluated whether mitragynine activates any of seven Gα<sub>i/o</sub> proteins coupled to α<sub>2A</sub>, α<sub>2B</sub>, and α<sub>2C</sub>Rs, as well as Gα<sub>q</sub> and Gα<sub>11</sub> coupled to α<sub>1A</sub>R. Additionally, we examined rat and human α<sub>2A</sub>R-mediated cAMP inhibition, α<sub>2A</sub>R-mediated β-arrestin2 recruitment, and tested α<sub>2</sub>R or α<sub>1</sub>R-mediated ERK phosphorylation in wild-type, β-arrestin 1/2 knockout, and Gα<sub>q/11</sub> knockout cells. Finally, we report binding and enzyme-inhibition profiling results for mitragynine and its major metabolites, 7-Hydroxymitragynine and 9-Hydroxycorynantheidine, at 99 targets. The results did not support the hypothesis that mitragynine (or its primary metabolites) activates α<sub>2</sub>Rs, but, aligned with our previous GTPγS results, demonstrate that mitragynine is a low-potency, competitive α<sub>2A</sub>R antagonist at Gα<sub>i1</sub>, cAMP, and β-arrestin2 transducers. However, we show that mitragynine is a low-potency (EC<sub>50</sub> ∼3 μM), partial agonist at α<sub>1A</sub>R-Gα<sub>11</sub> and stimulates ERK phosphorylation via Gα<sub>q/11</sub>-coupled α<sub>1</sub>Rs, supporting in vivo studies that suggest mitragynine is an α<sub>1</sub>R agonist. Nevertheless, the agonist effects of mitragynine at α<sub>1A</sub>R-Gα<sub>11</sub> were modest compared to clonidine, a partial agonist control that also activated all α<sub>2</sub>R transducers. Mitragynine's dual α<sub>2A</sub>R antagonist/α<sub>1</sub>R partial agonist pharmacology might contribute to mitragynine's psychostimulant-like properties.
Authors
- Marco Mottinelli (ORCID: https://orcid.org/0000-0001-5725-0439)
- Sushobhan Mukhopadhyay (ORCID: https://orcid.org/0000-0002-8947-0783)
- Nader H. Moniri (ORCID: https://orcid.org/0000-0002-8893-4339)
- Christopher R. McCurdy (ORCID: https://orcid.org/0000-0001-8695-2915)
- Samuel Obeng (ORCID: https://orcid.org/0000-0002-9644-0750)
- Aidan J. Hampson
- Clinton E. Canal (ORCID: https://orcid.org/0000-0002-7940-933X)
- Yiming Chen (ORCID: https://orcid.org/0000-0002-1311-7166)
- Richa Tyagi (ORCID: https://orcid.org/0009-0001-9228-6311)
- J. SETO
- Lance R. McMahon
Institutions
- Texas Tech University (US)
- National Institutes of Health (US)
- National Institute on Drug Abuse (US)
- Mercer University (US)
- Mercer University Health Sciences Center (US)
- University of Florida (US)
- Medicina (PL)
- Frequency Therapeutics (United States) (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- ACS Chemical Neuroscience
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1021/acschemneuro.5c00719
- Primary Topic
- Alkaloids: synthesis and pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00